Mohan Meera, Susanibar-Adaniya Sandra, Buros Amy, Crescencio Juan Carlos Rico, Burgess Mary J, Lusardi Katherine, Davies Faith, Morgan Gareth, Vanrhee Frits, Zangari Maurizio, Schinke Carolina, Thanendrarajan Sharmilan, Kothari Atul
Myeloma Institute, Little Rock, Arkansas.
Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Transpl Infect Dis. 2019 Apr;21(2):e13052. doi: 10.1111/tid.13052. Epub 2019 Feb 15.
Autologous stem cell transplantation (ASCT) is a commonly used treatment for multiple myeloma (MM). This retrospective cohort study characterizes the risk factors and outcomes associated with bacteremia following ASCT at a single center.
We conducted a retrospective analysis in subjects who underwent ASCT for multiple myeloma and other malignancies from May 2014 to March 2015 at a single center. The control cohort included all subjects undergoing ASCT in the same time period who did not develop bacteremia.
During the study period, 363 ASCTs were completed in 282 discrete patients. Bacteremia was documented in 13% of all transplants. Enterococcus faecium was the most frequent species overall (14/62, 23%). Vancomycin resistance was present in 93% of E faecium isolates. Bacteremia was associated with a significantly decreased survival in patients who received their transplant after the first year of myeloma treatment. Overall survival (OS) was not significantly different in the two cohorts among patients undergoing ASCT within the first year of myeloma treatment. Survival analysis showed a significantly decreased OS in patients who developed Enterococcus bacteremia as compared to the non-bacteremia cohort. Enterococcal bacteremia was associated with significantly longer duration of neutropenia (mean 14 vs 9.7 days, P = 0.01), hospitalization (mean 61.7 vs 20.4 days, P = 0.0006), and higher mortality (69% vs 25%, P = 0.01) as compared to other bacteremias.
We found a high incidence of E faecium and a low incidence of MRSA and Pseudomonas bacteremias following ASCT in our patient population. Survival analysis in our cohort suggests that the effect of underlying disease status and cumulative chemotherapy is critically important in determining outcomes related to bacteremia. Enterococcal bacteremias following ASCT were associated with significantly higher morbidity and mortality than non-enterococcal bacteremias.
自体干细胞移植(ASCT)是多发性骨髓瘤(MM)常用的治疗方法。这项回顾性队列研究描述了单中心ASCT后菌血症相关的危险因素和结局。
我们对2014年5月至2015年3月在单中心接受ASCT治疗多发性骨髓瘤和其他恶性肿瘤的患者进行了回顾性分析。对照组包括同期接受ASCT且未发生菌血症的所有患者。
在研究期间,282例不同患者完成了363次ASCT。所有移植中13%记录有菌血症。粪肠球菌是总体上最常见的菌种(14/62,23%)。93%的粪肠球菌分离株存在万古霉素耐药。菌血症与骨髓瘤治疗第一年之后接受移植的患者生存率显著降低相关。在骨髓瘤治疗第一年之内接受ASCT的患者中,两个队列的总生存期(OS)无显著差异。生存分析显示,与非菌血症队列相比,发生肠球菌菌血症的患者OS显著降低。与其他菌血症相比,肠球菌菌血症与中性粒细胞减少持续时间显著延长(平均14天对9.7天,P = 0.01)、住院时间显著延长(平均61.7天对20.4天,P = 0.0006)以及更高的死亡率(69%对25%,P = 0.01)相关。
我们发现,在我们的患者群体中,ASCT后粪肠球菌菌血症发生率高,耐甲氧西林金黄色葡萄球菌和铜绿假单胞菌菌血症发生率低。我们队列中的生存分析表明,基础疾病状态和累积化疗的影响在决定菌血症相关结局方面至关重要。ASCT后的肠球菌菌血症与非肠球菌菌血症相比,发病率和死亡率显著更高。